Cerebral Cavernous Malformation: Sequencing Panel

**Test Code:** MM410  
**Turnaround time:** 6 weeks  
**CPT Codes:** 81479 x3

### Condition Description

Cerebral cavernous malformations are collections of small blood vessels in the brain that are enlarged and irregular in structure. This condition is inherited in an autosomal dominant manner, with pathogenic variants in three genes (CCM1, CCM2, and CCM3) accounting for 85-95% of all cases. While the exact function of these genes is not fully understood, studies show that the proteins produced from these genes are found in the junctions connecting neighboring blood vessel cells. Pathogenic variants in these genes impair the function of the protein complex, resulting in weakened cell-to-cell junctions and increased leakage from vessels as seen in cerebral cavernous malformations.

Reference:

### Genes

- CCM2, KRIT1, PDCD10

### Indications

The test is indicated for:
- Individuals with a clinical or suspected diagnosis of cerebral cavernous malformation.

### Methodology

**Next Generation Sequencing:** In-solution hybridization of all coding exons is performed on the patient's genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not meant to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient's gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

### Detection

**Next Generation Sequencing:** Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's clinical/biochemical phenotype.

Analytical Sensitivity: ~99%.

### Specimen Requirements

Submit only 1 of the following specimen types

**Type: Whole Blood**

Specimen Requirements:
- In EDTA (purple top) tube:  
  - Infants (2 years): 3-5 ml  
  - Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.

**Type: Isolated DNA**

Specimen Requirements:
- In microtainer: 60 ug

Isolation using the Qiagen™ Puregene kit for DNA extraction is recommended.

Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/µl of TE buffer. Ship sample at room temperature with overnight delivery.

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.
Related Tests

- Cerebral Cavernous Malformation: Deletion/Duplication Panel